TherapeuticsMD Inc. (TXMD)

7.13
NASDAQ : Health Technology
Prev Close 6.88
Day Low/High 7.00 / 7.42
52 Wk Low/High 4.30 / 7.66
Avg Volume 3.02M
Exchange NASDAQ
Shares Outstanding 216.58M
Market Cap 1.49B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TherapeuticsMD Announces Multiple Presentations At The International Menopause Society's 16th World Congress

TherapeuticsMD Announces Multiple Presentations At The International Menopause Society's 16th World Congress

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the schedule of seven presentations at the International Menopause Society's 16 th World Congress on Menopause related to clinical data for Imvexxy™ (estradiol...

TherapeuticsMD To Present At Jefferies 2018 Healthcare Conference

TherapeuticsMD To Present At Jefferies 2018 Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will present at the Jefferies 2018 Healthcare Conference being held on June 5-8, 2018.

TherapeuticsMD Announces Clinical Abstract At The 2018 ASCO Annual Meeting

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the availability of clinical data from the REJOICE trial for IMVEXXY™ (estradiol vaginal inserts) (formerly TX-004HR).

TherapeuticsMD Comments On Media Reports Regarding TX-004HR

TherapeuticsMD Comments On Media Reports Regarding TX-004HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today commented on media reports that TX-004HR, the company's investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal...

Interesting TXMD Put And Call Options For July 20th

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Investor And Analyst Day On June 4

TherapeuticsMD Announces Investor And Analyst Day On June 4

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the Company will host an Investor and Analyst Day on Monday, June 4, 2018, in New York City.

TherapeuticsMD Announces First Quarter 2018 Financial Results

TherapeuticsMD Announces First Quarter 2018 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended March 31, 2018.

TherapeuticsMD To Host First Quarter Financial Results Conference Call And Webcast On May 3

TherapeuticsMD To Host First Quarter Financial Results Conference Call And Webcast On May 3

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its first quarter financial and business results on Thursday, May 3.

First Week Of TXMD December 21st Options Trading

Investors in TherapeuticsMD Inc saw new options become available this week, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

TherapeuticsMD Announces Expansion Of Board Of Directors

TherapeuticsMD Announces Expansion Of Board Of Directors

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the appointment of Jane F.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For TX-001HR

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For TX-001HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the acceptance of the NDA for TX-001HR by the U.

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the Company will participate in the Cowen and Company 38th Annual Healthcare Conference on March 12, and the Oppenheimer...

TherapeuticsMD Announces Fourth Quarter And Full Year 2017 Financial Results

TherapeuticsMD Announces Fourth Quarter And Full Year 2017 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its fourth quarter and full-year financial results for 2017.

TherapeuticsMD To Host Fourth Quarter And Year End 2017 Financial Results Conference Call And Webcast On February 20

TherapeuticsMD To Host Fourth Quarter And Year End 2017 Financial Results Conference Call And Webcast On February 20

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2017 financial and business...

TherapeuticsMD Announces Presentation At 36th Annual J.P. Morgan Healthcare Conference On January 10

TherapeuticsMD Announces Presentation At 36th Annual J.P. Morgan Healthcare Conference On January 10

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will present at the 36th Annual J.

TherapeuticsMD Announces Submission Of New Drug Application For TX-001HR

TherapeuticsMD Announces Submission Of New Drug Application For TX-001HR

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, announced today that it has submitted the New Drug Application (NDA) for TX-001HR, the company's investigational bio-identical hormone therapy...

TherapeuticsMD Announces FDA Acceptance Of New Drug Application And Prescription Drug User Fee Act (PDUFA) Date For TX-004HR

TherapeuticsMD Announces FDA Acceptance Of New Drug Application And Prescription Drug User Fee Act (PDUFA) Date For TX-004HR

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced the acceptance of the New Drug Application (NDA) resubmission for TX-004HR, the company's investigational applicator-free...

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, announced today that it has resubmitted the New Drug Application (NDA) for TX-004HR, the company's investigational applicator-free estradiol...

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will participate in the Stifel 2017 Healthcare Conference on November 14, and the Jefferies 2017 London...

TherapeuticsMD Announces Third Quarter 2017 Financial Results

TherapeuticsMD Announces Third Quarter 2017 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended September 30, 2017.

TherapeuticsMD Announces Plan To Resubmit The New Drug Application For TX-004HR

TherapeuticsMD Announces Plan To Resubmit The New Drug Application For TX-004HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the Company's investigational applicator-free...

TherapeuticsMD is Now Oversold (TXMD)

TherapeuticsMD is Now Oversold (TXMD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TherapeuticsMD To Host TX-004HR Regulatory Update And Third Quarter Financial Results Conference Call And Webcast On November 6

TherapeuticsMD To Host TX-004HR Regulatory Update And Third Quarter Financial Results Conference Call And Webcast On November 6

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss a TX-004HR regulatory update and third quarter financial...

First Week Of TXMD June 2018 Options Trading

First Week Of TXMD June 2018 Options Trading

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the June 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)